Vaxcyte (PCVX) Return on Capital Employed (2020 - 2026)
Vaxcyte (PCVX) reported Return on Capital Employed of 37.11% for Q1 2026, down 1812.0% year-over-year from 2.17% in Q1 2025, and down 15.78% quarter-over-quarter from 32.06% in Q4 2025.
Vaxcyte (PCVX) Return on Capital Employed (2020 - 2026) Analysis & Trends
Vaxcyte (PCVX) has 7 years of Return on Capital Employed data on file, last reported at 37.11% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 37.11%, down 1812.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 37.11% (down 1812.0% YoY), and the FY2025 annual result was 30.27%, down 572.0% from the prior year.
- Return on Capital Employed eased to 37.11% in Q1 2026 per PCVX's latest filing, from 32.06% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 16.77% in Q4 2024 and troughed at 47.12% in Q3 2022.
- A 5-year average of 29.75% and a median of 28.77% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2026: Return on Capital Employed jumped 2180 bps in 2023, then slumped 1812 bps in 2026.
- A 5-year view of Return on Capital Employed shows it stood at 34.74% in 2022, then decreased by 3 bps to 35.82% in 2023, then surged by 53 bps to 16.77% in 2024, then slumped by 91 bps to 32.06% in 2025, then dropped by 16 bps to 37.11% in 2026.
- Business Quant data shows PCVX's Return on Capital Employed at 37.11% in Q1 2026, 32.06% in Q4 2025, and 26.71% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -107.40% |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -50.43% |
| 10 | Vaxcyte | 6.34 Bn | 6.34 Bn | - | -37.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.11% |
| Dec 31, 2025 | -32.06% |
| Sep 30, 2025 | -26.71% |
| Jun 30, 2025 | -22.25% |
| Mar 31, 2025 | -18.99% |
| Dec 31, 2024 | -16.77% |
| Sep 30, 2024 | -22.37% |
| Jun 30, 2024 | -28.77% |
| Mar 31, 2024 | -30.76% |
| Dec 31, 2023 | -35.82% |
| Sep 30, 2023 | -25.32% |
| Jun 30, 2023 | -25.39% |
| Mar 31, 2023 | -27.68% |
| Dec 31, 2022 | -34.74% |
| Sep 30, 2022 | -47.12% |
| Jun 30, 2022 | -38.20% |
| Mar 31, 2022 | -35.61% |
| Dec 31, 2021 | -33.39% |
| Sep 30, 2021 | -30.23% |
| Jun 30, 2021 | -26.60% |